MABPHARM-B (02181) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results

Bulletin Express

Mar 12

Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026.

The agenda includes: 1. Reviewing and approving the consolidated annual results for the year ended 31 December 2025. 2. Authorising the publication of the FY2025 results. 3. Handling other routine corporate matters.

The notice was issued under the signature of Chairman Jiao Shuge on 12 March 2026 in Hong Kong.

The current board comprises: • Executive directors: Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu. • Non-executive directors: Mr. Jiao Shuge and Mr. Cen Jialin. • Independent non-executive directors: Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Louis Ho Ming Leung and Dr. Tao Qian.

Investors should note the forthcoming release of the FY2025 financial statements following the board meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1165772728"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165772728\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165772728?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165772728","market":"us","top_or_hot":-1,"title":"MABPHARM-B (02181) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results","media":"Bulletin Express","content":"<p>Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026.</p>\n<p>The agenda includes:  \n1. Reviewing and approving the consolidated annual results for the year ended 31 December 2025.  \n2. Authorising the publication of the FY2025 results.  \n3. Handling other routine corporate matters.</p>\n<p>The notice was issued under the signature of Chairman Jiao Shuge on 12 March 2026 in Hong Kong.</p>\n<p>The current board comprises:  \n• Executive directors: Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu.  \n• Non-executive directors: Mr. Jiao Shuge and Mr. Cen Jialin.  \n• Independent non-executive directors: Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Louis Ho Ming Leung and Dr. Tao Qian.</p>\n<p>Investors should note the forthcoming release of the FY2025 financial statements following the board meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MABPHARM-B (02181) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMABPHARM-B (02181) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-12 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026.</p>\n<p>The agenda includes:  \n1. Reviewing and approving the consolidated annual results for the year ended 31 December 2025.  \n2. Authorising the publication of the FY2025 results.  \n3. Handling other routine corporate matters.</p>\n<p>The notice was issued under the signature of Chairman Jiao Shuge on 12 March 2026 in Hong Kong.</p>\n<p>The current board comprises:  \n• Executive directors: Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu.  \n• Non-executive directors: Mr. Jiao Shuge and Mr. Cen Jialin.  \n• Independent non-executive directors: Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Louis Ho Ming Leung and Dr. Tao Qian.</p>\n<p>Investors should note the forthcoming release of the FY2025 financial statements following the board meeting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02181","symbol_name":"迈博药业-B","start_time":0,"source_url":"","article_id":"1165772728","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165772728","pubTimestamp":1773305055,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026. The agenda includes:   1. Reviewing and approving the consolidated annual results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02181":"迈博药业-B"},"translate_title":"MABPHARM-B(02181)计划于2026年3月26日召开董事会批准2025财年业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02181":1},"content_text":"Mabpharm Limited (stock code: 02181) announced that its board of directors will convene on Thursday, 26 March 2026.\nThe agenda includes:  \n1. Reviewing and approving the consolidated annual results for the year ended 31 December 2025.  \n2. Authorising the publication of the FY2025 results.  \n3. Handling other routine corporate matters.\nThe notice was issued under the signature of Chairman Jiao Shuge on 12 March 2026 in Hong Kong.\nThe current board comprises:  \n• Executive directors: Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu.  \n• Non-executive directors: Mr. Jiao Shuge and Mr. Cen Jialin.  \n• Independent non-executive directors: Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Louis Ho Ming Leung and Dr. Tao Qian.\nInvestors should note the forthcoming release of the FY2025 financial statements following the board meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}